Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 319: Zika Virus DNA Vaccine in Healthy Adults
NCT02840487Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2016
- Primary completion
- Mar 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VRC5288 in Zika virus infection (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and Tolerability of VRC-ZKADNA085-00-VP at 44 weeks. Started Aug 2016; status: completed.
02
Drugs
VRC5288
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT02840487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840487.